- Home
- ACRE vs CDXS Comparison
ACRE vs CDXS Comparison
Compare ACRE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- CDXS
- Stock Information
- Founded
- ACRE 2011
- CDXS 2002
- Country
- ACRE United States
- CDXS United States
- Employees
- ACRE N/A
- CDXS N/A
- Industry
- ACRE Real Estate Investment Trusts
- CDXS Major Chemicals
- Sector
- ACRE Real Estate
- CDXS Industrials
- Exchange
- ACRE Nasdaq
- CDXS Nasdaq
- Market Cap
- ACRE 358.1M
- CDXS 332.0M
- IPO Year
- ACRE 2012
- CDXS 2010
- Fundamental
- Price
- ACRE $6.39
- CDXS $5.28
- Analyst Decision
- ACRE Hold
- CDXS Buy
- Analyst Count
- ACRE 7
- CDXS 2
- Target Price
- ACRE $7.10
- CDXS $11.00
- AVG Volume (30 Days)
- ACRE 694.6K
- CDXS 875.4K
- Earning Date
- ACRE 02-20-2025
- CDXS 10-31-2024
- Dividend Yield
- ACRE 15.65%
- CDXS N/A
- EPS Growth
- ACRE N/A
- CDXS N/A
- EPS
- ACRE N/A
- CDXS N/A
- Revenue
- ACRE $39,423,000.00
- CDXS $64,446,000.00
- Revenue This Year
- ACRE N/A
- CDXS N/A
- Revenue Next Year
- ACRE N/A
- CDXS $2.02
- P/E Ratio
- ACRE N/A
- CDXS N/A
- Revenue Growth
- ACRE N/A
- CDXS N/A
- 52 Week Low
- ACRE $6.02
- CDXS $2.53
- 52 Week High
- ACRE $11.24
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- ACRE 36.68
- CDXS 59.97
- Support Level
- ACRE $7.04
- CDXS $5.42
- Resistance Level
- ACRE $7.27
- CDXS $6.01
- Average True Range (ATR)
- ACRE 0.21
- CDXS 0.39
- MACD
- ACRE -0.11
- CDXS -0.05
- Stochastic Oscillator
- ACRE 29.60
- CDXS 46.67
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.